ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Valuation Check After DAYBUE Growth Outlook And Pipeline Progress
Neuren Pharmaceuticals (ASX:NEU) moved back into focus after partner Acadia Pharmaceuticals projected DAYBUE global net sales of about US$700 million by 2028, along with FDA approval of the new DAYBUE STIX powder formulation.
See our latest analysis for Neuren Pharmaceuticals.
Even after a recent 3.7% pullback in the 1 day share price return to A$19.71, Neuren’s 7 day share price return of 5.1% and 1 year total shareholder return of 60.5% suggest momentum has been supported by DAYBUE updates...